PrecivityAD2, made by C2N Diagnostics, became the third FDA-cleared blood test for Alzheimer's disease when the agency cleared it on August 20, 2026, according to the Alzheimer's Association. It is also the first such test cleared for adults as young as 40, which matters directly to families facing symptoms well before the more familiar retirement-age picture of the disease, according to C2N Diagnostics.
For a family watching a parent, sibling, or spouse develop memory or thinking problems in their 40s or 50s, that lower age floor opens a door that older blood tests kept shut. The test does not diagnose Alzheimer's by itself, and it comes with specific conditions on who should get it and how the result should be used. The sections below lay out what the test actually measures, who qualifies, and the questions worth bringing to a clinician before or after taking it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the original research from NIH — Use this page to review the original research.
- Read the official guidance from Alz — Use this primary source to verify the official guidance.
Table of Contents
- What PrecivityAD2 Actually Measures
- Why the Age Range Matters for Younger-Onset Families
- What the Test Cannot Do
- Questions to Bring to a Clinician
- Where This Fits in a Larger Pattern of Blood Tests
- Frequently Asked Questions
What PrecivityAD2 Actually Measures
PrecivityAD2 does not detect Alzheimer's disease directly. It measures two pairs of proteins in a blood draw — plasma Aβ42/40 and p-tau217/np-tau217 ratios — and combines them into a single number called the Amyloid Probability Score 2, according to Practical Neurology.
That score estimates how likely it is that amyloid plaques, a hallmark protein buildup associated with Alzheimer's, are present in the brain. In the validation study behind the clearance, which involved 1,142 participants and checked results against PET scans or spinal fluid testing, a positive result had a 97.6% positive predictive value for amyloid pathology, and a negative result had a 93.1% negative predictive value, according to CLP Magazine. In practice, that means a positive or negative result is highly likely to match what a PET scan or spinal tap would show about amyloid — but it is still a probability score pointing toward amyloid, not a clinical diagnosis of Alzheimer's disease.
Why the Age Range Matters for Younger-Onset Families
The Alzheimer's Association defines younger-onset, or early-onset, Alzheimer's as disease that begins before age 65, most commonly showing up in a person's 40s or 50s, and it notes that diagnosis is often delayed because symptoms get blamed on stress, depression, or other causes, according to the Alzheimer's Association. A blood test cleared only for older adults has never addressed that group directly. PrecivityAD2's clearance for adults 40 and older changes that.
It is currently the only FDA-cleared Alzheimer's blood test usable in patients between 40 and 54, according to C2N Diagnostics. That gap exists because Roche's Elecsys pTau217 test, cleared four days later on August 24, 2026, is restricted to people 55 and older, according to the Alzheimer's Association. For a family with a 48-year-old showing cognitive symptoms, PrecivityAD2 is presently the only FDA-cleared blood option on the table.
What the Test Cannot Do
C2N's own clearance states that PrecivityAD2 is not cleared for population screening and is not a stand-alone diagnostic tool, according to C2N Diagnostics. It is meant to support a full clinical evaluation, not substitute for one.
That rules out using it as a general checkup item for someone with no symptoms, and it rules out treating the result as a final answer without a clinician's broader workup. The Alzheimer's Association's own clinical practice guideline on blood-based biomarker tests, first issued in 2025 and updated in July 2026, limits its recommendations to patients already being evaluated in specialized memory-disorder care, and it requires a test to hit at least 90% sensitivity and 75% specificity before it can even serve as a triage tool, according to the guideline, summarized on PubMed. The same guideline states that a positive triage-level blood result still needs to be confirmed with spinal fluid testing or an amyloid PET scan before a diagnosis is finalized, since blood tests alone do not yet meet the accuracy bar needed to replace those confirmatory tests, according to a summary of the guideline from BarcelonaBeta.
Questions to Bring to a Clinician
Walking into an appointment with the right questions can keep the conversation focused on what the result means for the specific person being evaluated. Consider raising: Each of these questions pushes the conversation toward what happens after the blood draw, which is where the real clinical decisions get made.
- Is this evaluation happening through a specialized memory-disorder clinic, which is the setting the current guideline is built around?
- If the result comes back positive, what confirmatory test — spinal fluid analysis or an amyloid PET scan — will follow before any diagnosis is made?
- Does the person's age and symptom pattern fit what PrecivityAD2 was validated for, since the clearance covers ages 40 and older with signs or symptoms of cognitive impairment, not asymptomatic screening?
- If the person is 55 or older, does it make sense to ask about Roche's Elecsys pTau217 test as well, since it was cleared days after PrecivityAD2 and may be run through a different lab relationship?
- What does a negative result change about the current differential diagnosis, given symptoms are already present and something is driving them?
Where This Fits in a Larger Pattern of Blood Tests
PrecivityAD2 is not the first Alzheimer's blood test the FDA has cleared — it is the third. Fujirebio's Lumipulse pTau217/β-amyloid 1-42 plasma ratio test held that first spot, cleared in May 2025, according to the Alzheimer's Association.
PrecivityAD2 followed in August 2026, and Roche's Elecsys pTau217 became a fourth option just four days later, restricted to ages 55 and up. That sequence means the field now has more than one cleared option, each with its own age range and intended use. For a younger-onset family, the practical takeaway is narrower than "there's a new Alzheimer's blood test": it is that PrecivityAD2 specifically is the one cleared to include people in their 40s and early 50s, and that distinction is what makes it relevant to a case that might otherwise have had no FDA-cleared blood test available at all.
Frequently Asked Questions
Can a primary care doctor order PrecivityAD2, or does it require a specialist?
The research packet does not specify ordering restrictions, but the Alzheimer's Association's guideline limits its recommendations to patients evaluated in specialized memory-disorder care, which is the setting to ask a clinician about.
Is PrecivityAD2 different from the Roche test cleared the same month?
Yes — PrecivityAD2 covers adults 40 and older, while Roche's Elecsys pTau217, cleared four days later, is limited to ages 55 and older, according to the Alzheimer's Association.
Does a positive PrecivityAD2 result mean someone has Alzheimer's disease?
No. It indicates a high probability of amyloid pathology in the brain, and the Alzheimer's Association's guideline calls for confirming that with spinal fluid testing or a PET scan before a diagnosis is made, according to BarcelonaBeta's summary.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: What Younger-Onset Alzheimer’s Families Should Know About the News
